Accelerated access to innovative medicines for patients in need

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 5, 2014, Pages 559-571

  Baird, L G ^a   Banken, R ^b   Eichler, H G ^c   Kristensen, F B ^d   Lee, D K ^e   Lim, J C W ^f   Lim, R ^e   Longson, C ^g   Pezalla, E ^h   Salmonson, T ⁱ   Samaha, D ^b   Tunis, S ^j   Woodcock, J ^k   Hirsch, G ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Institute national d'excellence en santé et services sociaux   (Canada)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

^d Danish Health and Medicines Authority   (Denmark)

^e HEALTH CANADA   (Canada)

^f HEALTH SCIENCES AUTHORITY   (Singapore)

^g NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^h AETNA   (United States)

ⁱ MEDICAL PRODUCTS AGENCY   (Sweden)

^j Center for Medical Technology Policy   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; EUROPEAN; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; INNOVATIVE MEDICINE; MEDICARE; MEDICINE; PATIENT CARE; REIMBURSEMENT; SINGAPORE; UNITED STATES; HEALTH CARE DELIVERY; HEALTH SERVICE; MEDICAL TECHNOLOGY; SUPPLY AND DISTRIBUTION;

DRUG;

BIOMEDICAL TECHNOLOGY; CANADA; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS; SINGAPORE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84908203910     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.145     Document Type: Article

References (31)

1. US Food and Drug Administration. Reports on post-marketing studies [FDAMA 130].
2. Moore, T. J. & Furberg, C. D. Development times, clinical testing, post-market follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration. JAMA Intern Med. 174, 90-95 (2014).
3. Federal Register. Report on the performance of drug and biologics firms in conducting post-marketing requirements and commitments; availability.
4. US Government Printing Office. Food and Drug Administration Safety and Innovation Act of 2012 (S-3187)
5. E ngelberg Center for Health Care Reform. Special medical use: limited use for drugs developed in an expedited manner to meet an unmet medical need.
6. E xecutive Office of the President. Report to the President on propelling innovation in drug discovery, development, and evaluation.
7. E uropean Medicines Agency. Press release: General principles-EMEAFDA parallel scientific advice.
8. E uropean Medicines Agency. Road map to 2015. The European Medicines Agency contribution to science, medicines, and health.
9. E uropean Medicines Agency. Work programme 2013.
10. E uropean Medicines Agency. Press release: European Medicines Agency launches adaptive licensing pilot project.
11. Health Canada. Regulatory roadmap for health products and food.
12. Health Canada. Blueprint for renewal: transforming Canada's approach to regulating health products and food.
13. E ichler, H. G. et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426-437 (2012).
14. Oye, K. et al. Legal foundations of adaptive licensing. Clin. Pharmacol. Ther. 94, 309-311 (2013).
15. US Census Bureau. Income, poverty and health insurance coverage in the United States: 2012.
16. Tunis, S. R., Berenson, R. A., Purrough, S. E. & Mohr, P. E. Improving the quality and efficiency of the Medicare program through coverage policy. Urban Institute.
17. Carino, T., Williams, R. D. 2nd, Colbert, A. M. & Bridger, P. Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy. Health Aff. (Millwood). 25, 1231-1239 (2006).
18. Mohr, P. E. & Tunis, S. R. Access with evidence development: the US experience. Pharmacoeconomics 28, 153-162 (2010).
19. Tunis, S. R. & Pearson, S. D. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff. (Millwood). 25, 1218-1230 (2006).
20. Carbonneil, C., Quentin, F. & Lee-Robin, S. H.; European network for Health Technology Assessment (EUnetHTA). A common policy framework for evidence generation on promising health technologies. Int. J. Technol. Assess. Health Care 25 (suppl. 2), 56-67 (2009).
21. Ferrario, A. & Kanavos, P. Managed entry agreements for pharmaceuticals: The European experience. LSE Research Online.
22. Klemp, M., Frønsdal, K. B. & Facey, K.; HTAi Policy Forum. What principles should govern the use of managed entry agreements? Int. J. Technol. Assess. Health Care 27, 77-83 (2011).
23. Kristensen, F. B. et al.; European network for Health Technology Assessment (EUnetHTA). Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. Int. J. Technol. Assess. Health Care 25 (suppl. 2), 1-8 (2009).
24. E uropean network for Health Technology Assessment. Overview of the EUnetHTA Project Results 2006-2008.
25. Quentin, F., Carbonneil, C., Moty-Monnereau, C., Berti, E., Goettsch, W. & Lee-Robin, S. H.; European network for Health Technology Assessment (EUnetHTA). Web-based toolkit to facilitate European collaboration on evidence generation on promising health technologies. Int. J. Technol. Assess. Health Care 25 (suppl. 2), 68-74 (2009).
26. E uropean network for Health Technology Assessment. EVIDENT Database. . Accessed 31 July 2013.
27. E uropean Commission. High Level Pharmaceutical Forum 2005-2008: Final Conclusions and Recommendations. . Accessed 31 July 2013.
28. E uropean network for Health Technology Assessment. Joint EUnetHTA-EMA Press Release. (2013).
29. US Food and Drug Administration. FY 2012 Innovative Drug Approvals. (2012). Accessed 13 November 2013.
30. DiMasi, J. A. Metrics on technical risks, clinical development times, and approval times for cancer drugs. (2013). Accessed 13 November 2013.
31. Barker, R. A flexible blueprint for the future of drug development. Lancet 374, 357-359 (2010).